The Shanghai Waigaoqiao Free Trade Zone recently launched a partner program and corresponding service package in an effort to establish itself as the top innovation hub for brain-computer interfaces (BCI).

Announced at the sixth Waigaoqiao Medical and Health Cooperation Forum on Nov 27, the initiative covers comprehensive support for cross-border R&D pilots, clinical approvals, and overseas market expansion.

"We're focusing on future technologies like BCI, synthetic biology, and AI-driven pharmaceuticals," said Zhu Yaopeng, general manager of Shanghai Waigaoqiao Biopharmaceutical Industry Development Co Ltd. "Our partner program aims to lead in these emerging fields and cultivate future industry leaders."

"We will strive to be pioneers in international personnel exchange, cross-border data flow, international medical services, and bonded R&D," said Zhu. "Our goal is to build a comprehensive service system and become the most trusted partner for companies in new drug and device development and global expansion."

BCI technology requires collaboration across medical and engineering disciplines. Waigaoqiao is regarded as an ideal hub as it boasts a strong industrial cluster covering innovative drugs, high-end medical devices, and cell therapy. Companies like StairMed are among the first to join the partner program.

StairMed has developed the world's smallest brain-controlled implant, capturing neural signals in milliseconds. In March, the company completed China's first clinical trial of an invasive BCI system. Their wireless BCI system is now under special review by China's medical regulatory body, a first in the country. "We plan large-scale clinical trials next year," said Assistant General Manager Chen Yaoxu. "Waigaoqiao is a true partner for tech companies navigating complex regulations."